Archive for February, 2012

A HEIDELBERG doctor is trying to relieve some of the pain for people suffering spinal cord injury.

David Berlowitz has been awarded a $50,000 Institute of Safety, Compensation and Recovery Research development grant to develop an integrated research database for spinal cord injury patients.

Dr Berlowitz, who works at Austin Health’s Institute for Breathing and Sleep and the Victorian Respiratory Support Service, said the project monitored the patient’s injury management and lifestyle for the rest of their lives.

He said the project, which he had been working on for more than a decade, would allow doctors to learn about how people are coping with their injury.

“We know what happens when they get the injury, but not what happens over the next 50 to 60 years,” Dr Berlowitz said.

“The research is really about trying to best establish a quality and safety register so we can see how people are living with the injury.

“The system we are going to use will be internationally recognised.”

He said there were 100 new spinal cord injuries in Victoria every year, and he was aiming to have a pilot program up and running within the next 18 months.

See more here:
Heidelberg doctor researches spinal cord injury

11-02-2012 13:48

More here:
cancer and regenerative medicine lecture - Video

HOLLISTON, Mass., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO - News), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that it has acquired the business of AHN Biotechnologie GmbH through its wholly owned Biochrom Ltd. subsidiary.

AHN is a privately held manufacturer of plastic consumable laboratory products including pipette tips. This acquisition is complementary to the current Biochrom product line of molecular biology instruments.

David Green, President of Harvard Bioscience, commented, "The acquisition of AHN Biotechnologie gives us a product line that is complimentary to the current Biochrom product line and also gives us a base of business in Germany for our entire molecular biology business. AHN will add approximately $2.5m in annual revenue and we expect this acquisition to be accretive to 2012 earnings per share."

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. HBIO sells products to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit http://www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6426

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expect," "plans," "estimates," "continue," "drive," "strategy," "crucial," "potential," "potentially," "growth," "long-term," "projects," "projected," "produce," "intends," "believes," "goals," "sees," "seek," "develop," "possible," "new," "enabling," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, including with respect to the impact of the Company's acquisition of AHN and the future performance of the acquired business, the field of regenerative medicine, opportunities or potential opportunities in the field of regenerative medicine, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts.

These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause the Company's actual results to differ materially from those in the forward-looking statements include the Company's inability to integrate the business acquired from AHN, the failure of the business acquired from AHN to perform in accordance with management's beliefs or expectations, the existence and size of opportunities in the neuroscience research market, the Company's failure to successfully expand its product offerings, introduce new products or commercialize new technologies, including in the field of regenerative medicine, decreased demand for the Company's products, including products in the field of regenerative medicine, due to changes in our customers' needs, our ability to obtain regulatory approvals, including FDA approval, for our products, including any products in the field of regenerative medicine, the current size or anticipated size of the regenerative medicine market, the existence and size of opportunities in the regenerative medicine market, our financial position, general economic outlook or other circumstances, overall economic trends, our ability to manage our growth, competition from our competitors, technological changes resulting in our products becoming obsolete, our ability to protect our intellectual property and operate without infringing on others' intellectual property, potential costs of any lawsuits to protect or enforce our intellectual property, research funding levels from endowments at our university customers, plus factors described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 or described in the Company's other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site http://www.harvardbioscience.com.

Read the original here:
Harvard Bioscience, Inc. Acquires AHN

RED BANK, NJ--(Marketwire -02/08/12)- American CryoStem Corporation (OTCQB: CRYO.OB - News), a commercial developer, manufacturer and marketer of clinical products and services involving adipose tissue and adipose derived adult stem cells, announced its association with the Alliance for Regenerative Medicine (ARM).

ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. American CryoStem's decision to join ARM was based on the alignment of its ongoing mission to offer the highest quality products and services to help accelerate the regenerative medicine industry and ARM's support of policy efforts toward safe and reliable cellular products.

Morrie Ruffin, Managing Director for the Alliance for Regenerative Medicine, commented, "We are delighted to have American CryoStem as part of the Alliance and look forward to working together to advance the field of adipose-derived stem cells for a variety of therapeutic applications."

ARM's membership is diverse, representing leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research and other organizations supporting regenerative medicine. American CryoStem has created and commercialized core proprietary products and platforms for processing, storing and quality management of adipose tissue and adipose derived adult stem cells that are broadly relevant to ARM's membership.

"American CryoStem is committed to working with industry organizations to develop cutting edge adipose tissue based treatments and therapies. One unique component of our clinical laboratory product and service suite is offering individuals the opportunity to cryogenically store their younger, healthier adult stem cells for their own future use in regenerative medicine," stated John Arnone, American CryoStem CEO. "We are pleased and honored to work with the Alliance for Regenerative Medicine to educate the public and regulators on the safe uses of adult stem cells and their potential life changing applications."

In support of these goals, the Company recently launched ACS Laboratories, thus expanding its clinical processing technology to companies, institutions and medical professionals. ACS Laboratories offers a wide range of adipose tissue specific services. Through ACS laboratories patented ACSelerate™ cell culture media, a ten product suite, American CryoStem can leverage its technology and products to participate in a broad range of clinical application opportunities.

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO.OB - News) markets clinical processing products and services for adipose (fat) tissue and adipose derived adult stem cells. CRYO's clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Go here to read the rest:
American CryoStem Joins Alliance for Regenerative Medicine

02-11-2011 18:46 The new drug Kalydeco is being hailed as a breakthrough in the treatment of cystic fibrosis, targeting the underlying genetic cause of the disease decreasing the symptoms. Dr. Jon LaPook reports.

Excerpt from:
CBS Evening News - Breakthrough in cystic fibrosis treatment - Video

26-01-2012 07:54 Air date: Wednesday, January 25, 2012, 3:00:00 PM Timedisplayed is Eastern Time, Washington DC Local Category: Wednesday Afternoon Lectures Description: Patients with diseased or injured organs may be treated with transplanted organs. There is a severe shortage of donor organs which is worsening yearly due to the aging population. Regenerative medicine and tissue engineering apply the principles of cell transplantation, material sciences, and bioengineering to construct biological substitutes that may restore and maintain normal function in diseased and injured tissues. Stem cells may offer a potentially limitless source of cells for tissue engineering applications and are opening new options for therapy. Recent advances that have occurred in regenerative medicine will be reviewed and applications of these new technologies that may offer novel therapies for patients with end-stage tissue and organ failure will be described. The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide. For more information, visit: The NIH Director's Wednesday Afternoon Lecture Series Author: Anthony Atala, MD, Wake Forest School of Medicine Runtime: 00:51:29 Permanent link: videocast.nih.gov

Read more from the original source:
Regenerative Medicine: Current Concepts and Changing Trends - Video

18-01-2012 15:53 Dr. Phillip Levy explains the science behind the revolutionary new Dr.Levy Switzerland anti-aging brand WORLD-RENOWNED ESTHETIC DERMATOLOGY PIONEER LEADING FACIAL REJUVENATION EXPERT // Number 1 Botox private doctor in Switzerland In today's world, nobody wants to look their age anymore, and many people seek to restore their skin's natural beauty. So what is so unique and new about your products? Dr. LEVY Switzerland®'s revolutionary Booster Cream and Booster Serum, are the world's first cosmetics, scientifically proven in vitro, to activate and vitalize both Dermal and Epidermal stem cells. Skin stem cells, it's important to remember, have unique anti-aging properties since they renew themselves as well as repair, replace and regenerate damaged skin. What are the extraordinary scientific advances behind the development of these special products ? In the last 2 years there have been 3 major discoveries involving advanced stem cell technology. One, in Montpellier, France, researchers were able to regenerate 101 year-old skin cells. They proved that not only did skin cells retain the memory of their youth, but that old cells could actually become young again ! Two, cardiologists in the United States published a study showing that the heart could be repaired by stem cells, even after a severe heart attack. And finally, researchers in Toronto Canada discovered the exact location of dermal stem cells, the very cells which are at the source of the skin's natural anti-wrinkle system. So ...

Follow this link:
Dr. Levy Switzerland - Video

08-02-2012 18:31 Dr Kevin Southern talks about gene therapy as a possible treatment for Cystic Fibrosis. He is interviewed by Caitlin. This film is part of the Changing Futures Project: http://www.changing-futures.co.uk.

Originally posted here:
Gene Therapy for Cystic Fibrosis - an Interview with Dr Kevin Southern - Video

03-02-2012 15:53 When Barry Goudy found out he had multiple sclerosis he feared the worst. Doctors told him he might lose his eye sight and the ability to walk. As a very active husband, father and hockey coach, Barry couldn't think of anything worse than losing his ability to get around. But then he learned of a new way to treat MS with a stem cell transplant. The transplant worked and today he's living proof of the miracles that can come from Adult Stem Cell Research.

Read more:
Adult Stem Cell Sucess Stories - Barry Goudy - Video

11-01-2012 23:04 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

Read the original here:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Shirlen M. Testimonial - Video

16-01-2012 03:59 http://www.telethon.it - Wiskott-Aldrich syndrome is a rare genetic disease that affects the immune system and increases a tendency to contract infections and experience haemorrhages. Alessandro Aiuti, a researcher at the San Raffaele-Telethon Institute of Milan explains the causes and tells us how today, thanks to Telethon's research, gene therapy can provide real hope for treatment for these patients.

View original post here:
Wiskott-Aldrich: new hope provided by gene therapy - Video

22-11-2011 11:13 (3:42) Yingxi Lin, a member of the McGovern Institute for Brain Research, uses molecular, genetic, and electrophysiological methods to understand how inhibitory circuits form within the brain, and how they are shaped by activity and experience. mcgovern.mit.edu - Learn more about Yingxi Lin [Stock footage courtesy of pond5 and Elekta Instrument AB]

Continue reading here:
Meet Yingxi Lin - Video

12-01-2012 16:34 UPDATE: For those of you who will say I get bad grades in school...In high school I was in the top 150 on my class and at Ohio University I have a 3.4 GPA and have made the Dean's List every single quarter/semester except for once when I was a decimal point shy. Also I'm very athletic and have been told I can easily make my college hoops team but I decide not to because it would take away a great deal of time from my social life and my girlfriend. Please share and get this out there! Also don't be afraid to comment whether supporting or enjoying a specific part of the piece or if you have a question. DOWNLOAD THE PAPER HERE: http://www.4shared.com

Link:
Proof Video Games Don't Cause Violence ~ A Research Paper - Video

14-11-2011 15:08 This tune is taken from the Genetic Identification EP released today on Dubsaw! Big release which you can buy here: http://www.beatport.com Find BIOMETRIX on FACEBOOK: http://www.facebook.com Find BIOMETRIX on YOUTUBE: http://www.youtube.com Find BIOMETRIX on TWITTER: http://www.twitter.com DarkstepWarrior: http://www.facebook.com soundcloud.com HardstepWarrior: http://www.youtube.com

Originally posted here:
Biometrix - Genetic Identification - Video

13-01-2012 06:26 The Lord will keep you safe from all evil; he will take care of your soul.Psalm 121:7 Youtube - They Sold Their Souls For Music Jesus is the Truth John 15-4 Baking Soda (SODIUM BICARBONATE) + hot water + drink = Cancer CURE (One teaspoon a week)

See more here:
Joe Rogan Pod cast Ron Paul genetic engineering. - Video

17-01-2012 05:07 DigInfo TV - diginfo.tv 22

Visit link:
"Low-Cadmium" Rice Through Genetic Modification #DigInfo - Video

15-12-2011 19:02 This is a comparison of predictions between two direct-to-consumer genetics companies, 23andMe and Navigenics. This study was conducted in 2009 and published in Nature 461:725 (October 2009 issue). Authors: Pauline C. Ng, Sarah S. Murray, Samuel Levy, J. Craig Venter

Read the rest here:
Personalized medicine: 23andMe

16-12-2011 14:26 Characterizing and Displaying Genetic Variants for Clinical Action Workshop December 1-2, 2011 More: http://www.genome.gov

Read more here:
Genome Enabled Electronic Medical Record (GenE EMR) - William Knaus - Video

06-01-2012 11:46 pennstatehershey.org In this episode of Medicine in Blue and White: The incredible connection between one fourteen year old boy -- and the thousands of people he has helped over the past forty years. Combining aerospace engineering and medical technology to help improve health care in developing countries. Never-before-seen-behavior under the microscope that could lead to a cure for some of the most challenging diseases we face. And a new way to test for what is -- literally -- an age-old problem.

Link:
Medicine in Blue and White - Episode 3 - Penn State Hershey Medical Center - Video

31-12-2011 03:40 In recent years, astonishing technological developments have pushed the frontiers of humanity toward far-reaching morphological transformation that promises in the very near future to redefine what it means to be human. An international, intellectual, and fast-growing cultural movement known as transhumanism intends the use of genetics, robotics, artificial intelligence, and nanotechnology (Grin technologies) as tools that will radically redesign our minds, our memories, our physiology, our offspring, and even perhaps—as Joel Garreau in his best-selling book, Radical Evolution, claims—our very souls. The technological, cultural, and metaphysical shift now underway unapologetically forecasts a future dominated by this new species of unrecognizably superior humans, and applications under study now to make this dream a reality are being funded by thousands of government and private research facilities around the world. As the reader will learn, this includes, among other things, rewriting human dna and combining humans with beasts, a fact that some university studies and transhumanists believe will not only alter our bodies and souls but ultimately could open a door to contact with unseen intelligence. http://www.ForbiddenGate.com http http://www.RaidersNewsNetwork.com http

Read this article:
Transhumanism - Genetic Manipulation - Tom Horn + Steve Quayle - Video

23-01-2012 20:59 1.5 years after a C4/C5 Spinal Cord Injury left him paralyzed from the shoulders down, Chris Leeuw continues Physical Therapy with Bioness and Electrical stimulation. An electric current stimulates atrophied muscles when the brain cannot - potentially helping patients learn to walk.

Excerpt from:
Bioness Therapy at Neuroworx; Spinal Cord Injury - Video

27-01-2012 11:54 Dave Bexfield went through an experimental NIH-sponsored clinical trial (HALT-MS) for his aggressive multiple sclerosis: a bone marrow stem cell transplant designed to stop disease progression. This video (Part 2) was done 17 months post transplant. Bexfield also runs http://www.ActiveMSers.org, a nonprofit website designed to help, motivate, and inspire those with multiple sclerosis to stay as active as possible—physically, intellectually, and socially—regardless of physical limitations. This film has been entered into the 2012 Neuro Film Festival from the American Academy of Neurology Foundation at http://www.neurofilmfestival.com. Let's put our brains together to support brain research. Visit http://www.neurofilmfestival.com.

Here is the original post:
Hope Renewed for MS Research - Video

06-02-2012 16:47 Salk scientists use an old theory to discover new targets in the fight against breast cancer Similarities between genetic signatures in developing organs and breast cancer could predict and personalize cancer therapies Reviving a theory first proposed in the late 1800s that the development of organs in the normal embryo and the development of cancers are related, scientists at the Salk Institute for Biological Studies have studied organ development in mice to unravel how breast cancers, and perhaps other cancers, develop in people. Their findings provide new ways to predict and personalize the diagnosis and treatment of cancer. In a paper published February 3 in Cell Stem Cell, the scientists report striking similarities between genetic signatures found in certain types of human breast cancer and those of stem cells in breast tissue in mouse embryos. These findings suggest that cancer cells subvert key genetic programs that guide immature cells to build organs during normal growth. "Stem cells in a healthy developing embryo have a GPS system to alert them about their position in the organ," says Geoffrey Wahl, a professor in Salk's Gene Expression Laboratory, who led the research. "The system depends on internal instructions and external signals from the environment to tell the stem cell what to do and where to go in the body. It stimulates the stem cells to grow and form more stem cells, or to change into different cells that form complex organs, such as the breast. Our ...

Read the original post:
Stem Cell Study Finds New Treatments For Breast Cancer - Video

11-01-2012 23:04 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

Continued here:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Shirlen M. Testimonial - Video

08-02-2012 23:17 NicholasAnderson.info Nicholas Anderson, Author of "NOC British Secret Operations" interviewed by Joseph Dowdy. stem cell transplantation... can't say diseases to get hopes up. oversaw exfiltration of doctor who is an expert at stem cell transplantation. not an expert or doctor, but can speak from experience. much of this may bother others. there is an assumption one belief is correct and others are wrong. stem cells are human and animal organisms derived from embryos. they can renew themselves in others bodys/cells/tissues. they are not factory assembled. they are coming from aborted tissue that would be thrown away. in the soviet union, they experimented on them. again, author does not know all about stem cells. speak to your doctor and do your own research. for most basic info on the doctor from the soviet union, see the book. was this post cold war debriefing? was he a scientist who knew a lot? no. he defected in mid-70s. the west/us/uk milked him for info. they did nothing with that info. he returned to the new russia after the collapse and started again. what has he been doing since? is the russian medicine better?? yes, it's more advanced or the west has simply got their advancements from russia. this is like a replacement battery for tissue/cells/body; it must be recharged. it does offer terminally ill chance to live longer; not a medical diagnosis. if people know enough about stem cells, they probably know what it is... it's good for regenerating tissue without ...

See the rest here:
Insights Into MI6: Stem Cell Transplantation - Video